Novartis AG: 1 director

A director at Novartis AG sold 55,000 shares at 90.477CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Infineon: Near-term downside priced in. Attractively valued for the lo...

As a follow-up to the work we published two weeks ago, which called for a downcycle in the auto semiconductor market, we review our expectations for Infineon. In summary, we expect Infineon to outperform the broader market, driven by a favorable exposure to xEVs and microcontroller share gains. We still see downside to expectations over the next 12 months, but from a stock perspective, we find the company attractively valued ahead of another leg of strong secular growth beyond this year.

Q1 shows core SOBI sales model works

Strong Q1 numbers, 20% CER growth and 5-15% adj EBITA beat. Vonjo questions remain, but Q1 shows that SOBI sales model works. EPS +1-2% and unchanged BUY, as core case is reaffirmed.

SK Hynix 1Q24 – strong demand; limited supply growth. Cycle thesis pla...

Hynix reported 1Q24 this morning.

Q1'24: strong sales and decent margin

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/23/2024

In the run-up to the 2024 Summer Olympic Games and Euro 2024 football tournament, we have identified six stocks to favour: JCDecaux, Accor, Sodexo, adidas, Unibail-Rodamco-Westfield and easyJet. While these two major sporting events are not expected to have a significant impact on the host economies in the medium term, the microeconomic and sectoral impacts should be more marked. The tourism, transport, beverages and consumer goods sectors are expected to be the main winners. Some med...

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 23/04/2024

En amont des Jeux Olympiques d’été et de l’Euro de football 2024, nous identifions 6 valeurs à privilégier  : JCDecaux, Accor, Sodexo, adidas, Unibail-Rodamco-Westfield et easyJet. Alors que ces deux évènements sportifs majeurs ne devraient pas avoir d’impact significatif sur les économies hôtes à moyen terme, les impacts microéconomiques et sectoriels devraient être plus marqués. Les secteurs du tourisme, des transports, des boissons et des biens de consommation devraient être les pr...

Coffee, Croissants & Credit/Verizon, SAP, Covivio

Telecom: Verizon reports mixed 1Q24 results

SAP: RDOS. 1T’24 (ANÁLISIS BANCO SABADELL)

Rdos. 1T'24 vs 1T'23: Ventas: 8.041 M euros (+8,1% vs +8,1% BS(e) y +7,9% consenso); EBIT non-IFRS: 1.533 M euros (+16,0% vs +22,3% BS(e) y +18,3% consenso). Rdos. 1T’24 en línea en ventas (+8,1% vs +8,1% BS(e) y +7,9% consenso) donde destacamos el comportamiento de Cloud (44% ventas), que presenta un crecimiento elevado aunque esperado (+24% vs 1T’23, en línea con nuestras estimaciones y las del consenso).

Novartis : Excellent Q1 results that justify an increase in the full-y...

>Q1 beats expectations for the top line (+4%) and bottom line (+7%) - Q1 came in ahead of expectations for sales (+4% vs consensus) and core EPS (+7% vs consensus). Sales grew 11% at CER (10% reported), driven by all the flagship products: Entresto (growth of 34%, +15% vs consensus), Cosentyx (23%, 10% vs cons.), Kisqali (51%, -2% vs cons.) and Kesimpta (66%, 0% vs cons.). Note that Pluvicto (47%, -3% vs cons.) once again undershot expectations and our estimates slig...

Novartis : Excellent T1 justifiant un relèvement de guidance FY

>T1 au-dessus des attentes sur la topline (+4%) et la bottom line (+7%) - Le T1 ressort au-dessus des attentes au niveau des ventes (+4% vs Css) et du core BPA (+7% vs Css). Les ventes progressent de 11% tcc (10% en publié) tirées par tous les produits phares : Entresto (34%, +15% vs Css), Cosentyx (23%, 10% vs Css), Kisqali (51%, -2% vs Css) et Kesimpta (66%, 0% vs Css). Notons que Pluvicto (47%, -3% vs Css) ressort une nouvelle fois légèrement en dessous des attente...

SAP : A good start to the year, but not enough (and too early) to rais...

>Solid Cloud & Software revenue, driven by on-premises resilience. Strong CCB - SAP released its Q1 2024 earnings yesterday after market. Sales were just in line, at € 8.04bn (css: € 8.02bn) but Cloud & Software revenue growth on cc came in at 11%, above expectations (css: 9% cc), thanks, again, to impressive resilience from the Support revenues (-1% cc vs css: -2.8% cc), while Cloud revenue growth was just in line with expectations (25% cc). The current Cloud backlo...

INFORME DIARIO 23 ABRIL + RDOS. ESPAÑA Y EUROPA 1T’24. PREVIEWS (ANÁLI...

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENAGÁS, ENCE, IAG, NATURGY, TALGO. EUROPA: SAP. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’24 que se publicarán en España y Europa en los próximos días. Rebota el mercado Las bolsas europeas recuperaron parte de las pérdidas de la semana pasada y el oro registró su mayor bajada en un año, siguiendo ...

SAP : A good start to the year, but not enough (and too early) to rais...

>Solid Cloud & Software revenue, driven by on-premises resilience. Strong CCB - SAP released its Q1 2024 earnings yesterday after market. Sales were just in line, at € 8.04bn (css: € 8.02bn) but Cloud & Software revenue growth on cc came in at 11%, above expectations (css: 9% cc), thanks, again, to impressive resilience from the Support revenues (-1% cc vs css: -2.8% cc), while Cloud revenue growth was just in line with expectations (25% cc). The current Cloud backlo...

Sartorius Stedim - More Downside to Come (SELL, TP EUR150 [165], 9 pgs...

The capitulation may be upon us. The order book continues to show weakness & contrary to the befuddling Q423 sales strength, equipment sales look likely to stay weak as CDMO’s reduce CAPEX after 3yrs of turbo charged growth. We now question the trend growth rate as we believe that market share gains will be minimal, CDMO CAPEX will recover very slowly & M&A is unlikely to contribute as much as it did in the past. Moreover, we expect DIM to add significant capacity in the coming 24mths, which is ...

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/18/2024

...

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 18/04/2024

...

Wedbush Morning Call - Apr 18 2024 7:09AM

Sartorius Stedim Biotech : Q1 review -Some stabilisation, but sales an...

>Q1 with some stabilisation – sales and order intake weaker than expected - Q1 2024 revenues of € 667m (-8.1% y-o-y,-2%/-4% vs ODDO BHF/consensus) were impacted by an organic decline of 9.4%. The decline in constant currencies was at -6.7%. Sartorius Stedim Biotech was impacted by mixed dynamics across its portfolio and regions. Demand continued to normalise the consumables business with positive order momentum, which indicates further progress in destocking. Simultan...